Allakos Inc (ALLK)
Allakos is a clinical stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. Co.'s antibodies are lirentelimab (AK002) and AK006. Co. is developing lirentelimab for the treatment of eosinophilic gastritis/eosinophilic duodenitis, eosinophilic esophagitis, atopic dermatitis, chronic spontaneous urticaria and potentially additional indications. AK006 targets Siglec-6, an inhibitory receptor selectively expressed on various cells. AK006 appears to have the potential to provide various cell inhibition than lirentelimab.
ALLK SEC Filing Email Alerts Service
| Company Name: |
Allakos Inc |
| Website: |
www.allakos.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding ALLK: |
14 |
| Total Market Value Held by ETFs: |
$11.90M |
| Total Market Capitalization: |
$189.00M |
| % of Market Cap. Held by ETFs: |
6.30% |
|
|
September 27, 2023 • 8:09 AM Eastern
Buy (2.62 out of 4)
9th percentile
|
|
Free ALLK Email Alerts:
